GlaxoSmithKline, Daiichi Sankyo join forces to sell vaccines in Japan

GlaxoSmithKline ($GSK) and Daiichi Sankyo ($D4S.BE) will jointly invest about $1.2 million and pool their vaccine operations into a 50/50 joint venture that they expect will be largest vaccine company in Japan. The Wall Street Journal points out that Japan's market has good growth potential because it currently uses many older vaccines and because the population is only beginning to vaccinate against some conditions that traditionally have been treated symptomatically. The deal is expected to be completed in the third quarter. Release | Story

Suggested Articles

After five years of struggles, Sun Pharmaceutical has put the problems at its key plant in Halol, India behind it.

Pfizer says two lots of migraine med Relpax failed to meet microbial standards and may be contaminated with genera pseudomonas and burkholderia.

Emcure has had its share of run-ins with the FDA in the past over the sterility of its plants. Now, it can notch one more black mark on its belt.